BERN, Switzerland and SAN DIEGO, Calif. — Topcon Healthcare has officially announced it will be the lead investor for machineMD, a medical device company focused on neurodiagnostic innovation. This partnership aligns with Topcon Healthcare’s mission to deliver Healthcare from the Eye, enhancing access to high-quality care while optimizing health care costs.
Topcon Healthcare has joined machineMD’s pre-Series A funding round as the lead investor, underscoring a shared commitment to advancing neurodiagnostics through ocular data. This collaboration will integrate machineMD’s objective functional neurodiagnostics with Topcon’s Harmony digital health information platform, fostering earlier detection of neurological diseases within a connected care ecosystem.
Founded with a vision to enable faster, more accurate, and earlier diagnoses of neurological disorders, machineMD is pioneering oculometric analysis to assess brain function with precision. By leveraging neurodiagnostic expertise, the company is developing solutions that support individuals affected by conditions such as multiple sclerosis and Parkinson’s Disease.
Neurodiagnostics
“Topcon Healthcare and machineMD share a bold ambition to shape the future of neurodiagnostics — making it more accessible, scalable, and data-driven,” said Dominic Senn, CEO and Co-founder of machineMD. “With the backing of forward-thinking partners like Topcon Healthcare and our expanding network of clinical experts, we are accelerating our journey to establishing neurodiagnostics as the standard of care — ultimately improving millions of lives.”
Topcon Healthcare’s pioneering initiative, Healthcare from the Eye, utilizes ocular data to identify ocular, systemic, or neurological disease in a coordinated care system that includes eye care providers, primary care providers, and specialty care providers using secure and responsible technology. Through this partnership, machineMD’s neurodiagnostic capabilities will be integrated into Topcon Healthcare’s multimodal retinal imaging technologies, unlocking faster, cost-effective pathways for neurological disease detection and management.
machineMD’s flagship product, neos, leverages virtual reality (VR) technology and gamified visual stimuli to capture precise oculomotor and pupillometric data. Already in clinical use across Switzerland and the USA, neos is streamlining workflows, paving the way for scalable and reimbursable neurodiagnostics.
Clues in the retina
“Our investment in machineMD reflects our commitment to expanding ocular-based diagnostics into the realm of neurological diseases,” said Ali Tafreshi, CEO and President of Topcon Healthcare, Inc.. “machineMD’s expertise and cutting-edge technology will enable more precise and earlier diagnoses, ultimately improving patient outcomes.”
By combining machineMD’s neurodiagnostic functional biomarkers with Topcon Healthcare’s multimodal retinal imaging-based biomarkers, the partnership will enhance clinical decision-making and patient management. Delivering these innovations through the Harmony cloud-based platform will create a seamless digital ecosystem for ocular and neurological diagnostics, empowering health care professionals with integrated data-driven insights.
Together, Topcon Healthcare and machineMD are ushering in a new era of predictive, preventive, and personalized medicine for neurological and systemic diseases — driving earlier intervention, optimized health care utilization, and improved patient outcomes worldwide.
Author
